Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

导出原文传递

翻译打印收藏纠错

作者： Wynn, Daniel ^[1] ; Kaufman, Michael ^[2] ; Montalban, Xavier ^[3] ; Vollmer, Timothy ^[4] ; Simon, Jack ^[5] ; Elkins, Jacob ^[6] ; O'Neill, Gilmore ^[7] ; Neyer, Lauri ^[8] ; Sheridan, James ; Wang, Chungchi ; Fong, Alice ; Rose, John W.

作者单位： Biogen Idec Inc, Cambridge, MA USA ^[1] Univ Colorado, Bioimaging Res Lab, Denver, CO 80202 USA ^[2] Univ Utah, Ctr Adv Med Technol, Salt Lake City, UT USA ^[3] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA ^[4] Neurol Multiple Sclerosis Ctr, Northbrook, MA USA ^[5] Facet Biotech, Redwood City, CA USA ^[6] Hosp Univ Vall Hebron, Barcelona, Spain ^[7] Carolinas Med Ctr, Charlotte, NC 28203 USA ^[8]

发布时间 2016-01-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Lancet Neurology

2010年9卷4期

381-390页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Lancet Neurology

相似文献

Lancet Neurology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Lancet Neurology

相似文献

Lancet Neurology

相关期刊

检索历史清除